VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (TSXV:NGEN) (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the Company will ring the closing bell at the Nasdaq Stock Market (Nasdaq) on Thursday, January 22, 2026 in New York City.

Adam Rogers, MD, Chairman and Interim Chief Executive Officer will be joined by members of the NervGen management team, Board of Directors, advisors, and other guests.

"We are honored to participate in the Nasdaq closing bell ceremony and highlight NervGen's mission to transform the lives of individuals living with spinal cord injury by enabling the nervous system to repair itself," said Adam Rogers, MD, Interim Chief Executive Officer of NervGen Pharma. "Becoming a Nasdaq-listed company represents a significant milestone in the growth and evolution of NervGen. This latest accomplishment was made possible through the unwavering support of our shareholders, physician and scientific collaborators, advocacy partners, the individuals and families who have placed their trust in NervGen by participating in our clinical research, and our dedicated management team and advisors."

The broadcast will begin at 3:45 pm ET and will be livestreamed from the Nasdaq MarketSite Tower in New York City and available on Nasdaq's X and Facebook pages.

About NervGen Pharma

NervGen Pharma Corp. (TSXV:NGEN) (NASDAQ:NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company's mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen's lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide. NVG-291 was evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with chronic SCI between 1 to 10 years post-injury and is the first pharmacologic candidate to demonstrate durable improvement in function, independence, and quality of life. Enrollment of individuals with subacute SCI in the Phase 1b/2a CONNECT SCI Study is ongoing, alongside preparation for a Phase 3 clinical trial in chronic SCI. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI. Through NVG-291 and the Company's next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.

Contacts

Huitt Tracey, Investors

htracey@nervgen.com

604.537.2094

David Schull or Ignacio Guerrero-Ros, Ph.D., Media

Russo Partners

David.Schull@russopartnersllc.com

Ignacio.Guerrero-Ros@russopartnersllc.com

858.717.2310

Bill Adams, Chief Financial Officer

info@nervgen.com

778.731.1711

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note and Forward Looking-Statements

This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the expected benefits from the Nasdaq listing; NVG-291's potential to become the first approved pharmacologic therapy for SCI; the Company's plans for future regulatory meetings; the Company's potentially best-in-class candidate, NVG-291; the potential broad therapeutic applications of NVG-291; the future growth of the Company; the Company's mission to transform the lives of individuals living with spinal cord injury; the Company's pursuit to revolutionize the treatment paradigm for neurotraumatic conditions with significant unmet medical need; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and final results from our clinical trials of NVG-291 in individuals with spinal cord injury; and the creation of neuroreparative therapeutics to enable the nervous system to repair itself in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: its ability to obtain future funding on favorable terms, if at all; the accuracy of its financial projections; obtaining positive results in its clinical trials; its ability to obtain necessary regulatory approvals; its ability to arrange for the manufacturing of its product candidates and technologies; and general business, market and economic conditions. Many factors could cause the Company's actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the Company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at www.sedarplus.ca and in NervGen's Form F-10/A filed on EDGAR at www.edgar.com. All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing